Piramal Pharma Solutions opens a new payload-linker suite in Michigan as part of a $90 million US investment plan, bolstering its ADC manufacturing capabilities across sites in Riverview and Lexington.
US contract development and manufacturing organization (CDMO) Piramal Pharma Solutions (PPS), part of India-headquartered Piramal Pharma, plans to invest $80 million for the expansion of its Lexington, Kentucky, facility.
Piramal Pharma Solutions has announced plans to invest a total of £55 million in two expansions at Grangemouth, Scotland, and Morpeth, UK. The Indian CDMO said the projects have been driven by several pipeline products moving to commercial scale, coupled with increased customer demand for antibody-drug conjugates (ADCs) and APIs.
Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.
